DBV Technologies (NASDAQ:DBVT) Stock Price Target Cut by Guggenheim

DBV Technologies (NASDAQ:DBVT) had its price target reduced by investment analysts at Guggenheim from $51.00 to $46.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim‘s price target points to a potential upside of 358.85% from the company’s previous close.

DBVT has been the topic of several other reports. Wall Street Zen cut shares of DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. Citigroup reiterated a “market outperform” rating on shares of DBV Technologies in a report on Thursday. Weiss Ratings restated a “sell (e+)” rating on shares of DBV Technologies in a report on Thursday, October 15th. HC Wainwright reiterated a “buy” rating on shares of DBV Technologies in a report on Friday. Finally, Citizens Jmp decreased their target price on DBV Technologies from $55.00 to $47.00 and set a “market outperform” rating for the company in a report on Thursday. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $45.25.

DBV Technologies Price Performance

DBVT opened at $10.03 on Friday. DBV Technologies has a 12 month low of $8.63 and a 12 month high of $26.18. The business has a 50 day simple moving average of $11.62 and a 200-day simple moving average of $16.97. The stock has a market capitalization of $630.35 million, a P/E ratio of -3.33 and a beta of -1.04.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Wednesday, October 28th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.44). DBV Technologies had a negative return on equity of 115.81% and a negative net margin of 5,392.17%. The business had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $0.56 million. Research analysts anticipate that DBV Technologies will post -2.05 EPS for the current year.

Hedge Funds Weigh In On DBV Technologies

Hedge funds and other institutional investors have recently made changes to their positions in the business. Perceptive Advisors LLC bought a new position in DBV Technologies in the 1st quarter valued at about $20,146,000. Elmind Capital LP acquired a new position in DBV Technologies during the first quarter worth about $5,536,000. Dorsey Wright & Associates bought a new stake in DBV Technologies in the first quarter worth about $2,142,000. Diversify Wealth Management LLC bought a new stake in DBV Technologies in the first quarter worth about $1,293,000. Finally, Vivo Capital LLC lifted its holdings in DBV Technologies by 8.4% in the 1st quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock valued at $55,726,000 after acquiring an additional 205,943 shares during the last quarter. 71.74% of the stock is currently owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.

DBV Technologies’ lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.